Neuland Laboratories Ltd

Neuland Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Neuland Laboratories Ltd

₹ 16,590 -0.54%
15 May - close price
neulandlabs.com BSE: 524558 NSE: NEULANDLAB
About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Key Points

Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]

Website BSE NSE
  • Market Cap ₹ 21,285 Cr.
  • Current Price ₹ 16,590
  • High / Low ₹ 19,748 / 11,011
  • Stock P/E 58.5
  • Book Value ₹ 1,461
  • Dividend Yield 0.07 %
  • ROCE 26.6 %
  • ROE 21.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.7% CAGR over last 5 years

Cons

  • Stock is trading at 11.4 times its book value
  • Promoter holding has decreased over last 3 years: -3.50%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Smallcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
407 363 418 393 385 440 311 398 328 293 514 440 776
287 266 280 272 278 316 249 311 277 258 359 363 469
Operating Profit 120 97 137 121 107 123 62 87 51 34 156 77 307
OPM % 29% 27% 33% 31% 28% 28% 20% 22% 16% 12% 30% 18% 40%
8 2 3 2 5 25 4 60 7 8 2 8 12
Interest 4 2 4 4 4 3 1 2 2 5 5 7 7
Depreciation 13 14 15 15 16 16 16 16 17 20 23 24 25
Profit before tax 110 83 122 104 92 130 49 128 39 18 129 54 287
Tax % 23% 26% 27% 22% 27% 25% 34% 20% 29% 21% 25% 26% 26%
85 62 89 81 68 98 33 102 28 14 97 41 213
EPS in Rs 65.89 48.23 69.56 63.44 52.66 76.28 25.60 79.18 21.68 10.83 75.49 31.62 165.76
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
469 510 579 527 667 763 937 951 1,191 1,559 1,477 2,023
402 430 472 477 608 661 790 807 918 1,096 1,146 1,448
Operating Profit 67 80 106 51 58 102 147 144 273 463 331 574
OPM % 14% 16% 18% 10% 9% 13% 16% 15% 23% 30% 22% 28%
0 2 1 4 3 4 16 0 9 12 90 30
Interest 27 24 21 19 16 22 18 14 13 14 8 24
Depreciation 15 16 19 22 26 31 40 49 53 60 66 92
Profit before tax 25 42 67 14 20 53 105 82 216 401 346 489
Tax % 36% 36% 30% 13% 19% 69% 23% 22% 24% 25% 25% 26%
16 27 47 12 16 16 81 64 164 300 260 364
EPS in Rs 17.96 30.75 52.74 13.57 12.81 12.63 62.85 49.74 127.45 233.89 202.74 283.71
Dividend Payout % 8% 7% 0% 0% 0% 16% 8% 10% 8% 6% 6% 12%
Compounded Sales Growth
10 Years: 15%
5 Years: 17%
3 Years: 19%
TTM: 37%
Compounded Profit Growth
10 Years: 30%
5 Years: 39%
3 Years: 30%
TTM: 75%
Stock Price CAGR
10 Years: 35%
5 Years: 49%
3 Years: 80%
1 Year: 50%
Return on Equity
10 Years: 14%
5 Years: 18%
3 Years: 21%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 9 9 9 13 13 13 13 13 13 13 13
Reserves 152 178 537 549 686 697 774 828 981 1,270 1,512 1,862
188 182 192 319 231 264 182 241 128 95 157 301
162 155 148 194 200 257 356 302 457 454 498 754
Total Liabilities 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180 2,930
123 139 466 475 542 653 716 767 758 824 955 1,178
CWIP 41 40 20 126 104 24 17 20 41 46 48 210
Investments 7 7 8 8 8 8 7 4 1 1 109 2
340 337 393 463 476 547 585 592 781 962 1,068 1,541
Total Assets 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180 2,930

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
13 45 39 11 70 57 189 60 237 261 317 347
-14 -20 -42 -116 -77 -49 -84 -95 -61 -150 -298 -424
1 -24 -0 105 12 -5 -114 38 -136 -69 25 21
Net Cash Flow 0 1 -4 -0 5 3 -9 3 40 42 44 -56
Free Cash Flow -1 26 -2 -121 7 9 84 -37 173 119 112 -50
CFO/OP 33% 70% 52% 28% 128% 61% 132% 56% 103% 81% 119% 78%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 100 85 114 134 90 91 85 90 111 87 78 98
Inventory Days 170 182 186 266 191 209 205 227 211 220 238 247
Days Payable 167 121 118 189 118 110 126 100 129 121 156 130
Cash Conversion Cycle 103 147 182 211 162 190 164 216 193 187 160 214
Working Capital Days 11 26 44 38 138 137 60 74 81 88 76 75
ROCE % 16% 18% 16% 4% 4% 8% 11% 10% 21% 33% 19% 27%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Fixed Asset Turnover
x ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of Active CMS Projects
Count ・Standalone data
Total Reactor Volume
Liters ・Standalone data
Number of Active US DMFs
Count ・Standalone data
Number of Countries Served
Count ・Standalone data
Total DMFs Filed Worldwide
Count ・Standalone data
R&D Scientist Count
Count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
36.03% 35.97% 32.80% 32.74% 32.72% 32.64% 32.68% 32.67% 32.67% 32.64% 32.63% 32.63%
20.19% 21.57% 22.69% 24.43% 25.72% 26.46% 23.86% 22.12% 21.69% 20.60% 20.90% 20.46%
6.76% 6.99% 6.02% 6.54% 6.39% 6.38% 9.09% 10.97% 11.57% 13.55% 14.72% 15.84%
0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.00% 0.00%
36.62% 35.08% 38.10% 35.88% 34.77% 34.12% 33.96% 33.85% 33.67% 32.80% 31.76% 31.08%
No. of Shareholders 25,22326,82427,72328,61629,07734,56739,31539,33342,41944,39346,18746,304

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls